CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.
Cheng, Mangeng; Quail, Matthew R; Gingrich, Diane E; Ott, Gregory R; Lu, Lihui; Wan, Weihua; Albom, Mark S; Angeles, Thelma S; Aimone, Lisa D; Cristofani, Flavio; Machiorlatti, Rodolfo; Abele, Cristina; Ator, Mark A; Dorsey, Bruce D; Inghirami, Giorgio; Ruggeri, Bruce A.
Mol Cancer Ther
; 11(3): 670-9, 2012 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-22203728
Where is the Future of Drug Discovery for Cancer?
Targeting of Fn14 Prevents Cancer-Induced Cachexia and Prolongs Survival.
MED12 controls the response to multiple cancer drugs through regulation of TGF-ß receptor signaling.
Transcriptional Addiction in Cancer.
In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system.
The PI3K Pathway in Human Disease.
Cellular metabolism and disease: what do metabolic outliers teach us?
Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy.
Targeting Metabolic-Redox Circuits for Cancer Therapy.
AMPK: opposing the metabolic changes in both tumour cells and inflammatory cells?